Whereas clinical trials for the treatment of prostate cancer with orteronel were terminated in phase III because of a lack of significant effect on OS [54,58,103], it is currently being investigated in a phase II clinical study of women with AR-positive metastatic TNBC (NCT01990209). The gene discussed is AR; the disease is prostate cancer.